Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

25 févr. 2019 08h00 HE | Source: Tyme Technologies, Inc.

TYME Receives FDA Guidance on Pivotal Trial for SM-88 in Treatment for Advanced Pancreatic Cancer

NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing metabolic-based cancer therapies, announced that it received design...
14 févr. 2019 08h00 HE | Source: Tyme Technologies, Inc.

TYME Reports Encouraging SM-88 Clinical Results without Typical Hormone-Related Side Effects in Phase II Study of Patients with Biomarker Recurrent Prostate Cancer

SM-88 therapy did not exhibit typical side effects associated with hormonal castration from androgen-deprivation therapy (ADT)87% of patients (20/23) remained free of radiographic progressionAfter 12...
11 févr. 2019 07h30 HE | Source: Tyme Technologies, Inc.

TYME Reports Third Quarter Fiscal 2019 Financial and Operating Results

TYME’s novel metabolic-based investigational cancer therapy, SM-88, demonstrated encouraging results and a well-tolerated safety profile in a preliminary analysis from a Phase II study of patients...
18 janv. 2019 08h00 HE | Source: Tyme Technologies, Inc.

TYME’s Novel Metabolic-Based Cancer Therapy, SM-88, Improves Survival in Phase II Study of Patients with Advanced Pancreatic Cancer

68% of evaluable patients with actively progressing end-stage pancreatic cancer receiving monotherapy SM-88 remain alive with a median follow-up of 4.3 months (median 5.8 months from completing last...
15 janv. 2019 08h00 HE | Source: Tyme Technologies, Inc.

Tyme Schedules Conference Call to Discuss SM-88 Preliminary Phase II Pancreatic Cancer Data on Friday, January 18th

NEW YORK, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), a clinical-stage oncology biotechnology company developing metabolically-based cancer therapeutics, today...
04 janv. 2019 08h00 HE | Source: Tyme Technologies, Inc.

Tyme Announces the Presentation of SM-88 Data at the 2019 ASCO Genitourinary Cancers Symposium

NEW YORK, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced that it will...
26 nov. 2018 16h01 HE | Source: Tyme Technologies, Inc.

Tyme Technologies, Inc. to Present at the Piper Jaffray Healthcare Conference on November 28th

NEW YORK, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today...
26 nov. 2018 08h00 HE | Source: Tyme Technologies, Inc.

Tyme Announces the Presentation of Clinical Abstracts at the 2019 Gastrointestinal Cancers Symposium

NEW YORK, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced that it will...
20 nov. 2018 16h45 HE | Source: Tyme Technologies, Inc.

Tyme Technologies, Inc. to Present at the Evercore ISI, HealthconX Conference on November 27th

NEW YORK, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today...
08 nov. 2018 16h30 HE | Source: Tyme Technologies, Inc.

Tyme, Inc. to Present at the Stifel 2018 Healthcare Conference on November 13th

NEW YORK, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), a clinical stage biotechnology company developing cancer therapeutics for pancreatic, prostate and sarcoma tumors,...

Page précédente